Core Viewpoint - Scienture Holdings, Inc. has successfully completed a draw on its Equity Line of Credit (ELOC) to support the commercial launch of its FDA-approved product, Arbli, while temporarily suspending further draws until certain conditions are met [1][2][3]. Financial Strategy - The draw on the ELOC is aimed at providing immediate capital for pre-launch activities of Arbli, the first FDA-approved ready-to-use oral liquid losartan in the U.S. market [2]. - The company has decided to pause further ELOC draws for 30 trading days or until its stock price reaches $10 per share, indicating confidence in its business prospects [3]. Product Information - Arbli is a novel antihypertensive medication indicated for treating hypertension in patients over 6 years old, reducing stroke risk in patients with hypertension and left ventricular hypertrophy, and treating diabetic nephropathy in certain type 2 diabetes patients [4]. - The product is available in a 165 mL peppermint-flavored suspension that does not require refrigeration and has an 18-month shelf life when stored at room temperature [5]. Company Overview - Scienture Holdings, Inc. operates through its subsidiaries, focusing on providing enhanced value to patients and healthcare systems by developing and distributing specialty pharmaceutical products [6]. - The company is committed to addressing unmet market needs and has a team of experienced professionals dedicated to bringing unique specialty products to market [6].
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days